text:
EX-99.4
5
a07-29914_1ex99d4.htm
EX-99.4
Exhibit 99.4
Contact
:
Dominic Petrucci
Chief Operating Officer
Cornerstone Ventures, Inc.
949 263 4340
dpetrucci@cvinc.net
Cornerstone Core Properties REIT, Inc.
Announces $37.2 Million
Definitive Agreement to Purchase Orlando
Small Bay Multi-Tenant Industrial Properties
Irvine, CA - November 21, 2007
- Cornerstone
Core Properties REIT, Inc (CCP REIT) announced today it has entered into a
definitive agreement to purchase an existing multi-tenant industrial property
known as Orlando Small Bay for a purchase price of $37.2 million.
Orland Small Bay consists of four industrial business parks with 18
buildings and 92 separate units. The properties are 95% leased to 87 different
tenants whose spaces range in size from approximately 1,200 square feet to approximately
22,500 square feet. Tenants of Orlando Small Bay are engaged in varying
businesses including light manufacturing, warehouse distribution and service
related businesses. The property has approximately 394,471 square feet of space
situated on approximately 34 acres of land and is ideally located in the
metropolitan Orlando, Florida area. All four parks are well positioned to
capitalize on their in-fill locations (creating barriers to entry), ease of
access, and high visibility.
Metropolitan
Orlando's central location offers almost equidistant access to the state's
other major metropolitan centers, positioning the region as a hub with quick,
easy access to air, land and water transportation routes. The networks of air
routes, rail systems and interstate highways, as well as nearby deep-water
ports, are attractive to various manufacturing, warehouse and distribution
businesses that typically require industrial properties similar to those at
Orlando Small Bay.
Scarcity of
available industrial land in Central Florida combined with rising construction
costs have made it difficult for developers to get a foothold in the Orlando
industrial market. According to Torto Wheaton Research, the overall vacancy
rate for the Orlando industrial market was only 6.7% at the end of the third
quarter 2007.
CCP REIT is a publicly offered, non-traded real estate company
investing primarily in multi-tenant industrial properties located in major
metropolitan markets throughout the United States. While the CCP REIT may use
some degree of debt financing for acquisition, working capital, tenant
improvements, capital improvements and cash distributions, it intends to own
and operate its properties on an all-cash basis thus mitigating foreclosure and
interest rate risk.
This release may contain forward-looking statements with the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, including discussions regarding Cornerstone Core
Properties REIT, Inc's use of proceeds and certain other factors that may
affect future earnings or financial results. Such statements involve risk and
uncertainties which could cause actual results to vary materially form those
expressed in or indicated by the forward-looking statements. Factors that may
cause actual results to differ materially include changes general economic
conditions, changes in real estate conditions, construction delays, changes in
interest rates, lease-up risks, lack of financing availability and lack of
capital proceeds. This is not an offer or a solicitation to purchase securities.
Such an offer can be made only by means of a prospectus that includes more
complete information on the fees and risk factors involved. Investors should
read a prospectus carefully before investing. To obtain a prospectus, please
contact your investment professional or Pacific Cornerstone Capital, Inc. at
1920 Main Street, Suite 400, Irvine, CA 92614 (877 805 3333). Securities
offered through Pacific Cornerstone Capital, Inc. Member FINRA and SIPC.
Investments are not FDIC insured, not bank guaranteed and may lose value.

text: Dominic Petrucci

text: Cornerstone Core Properties REIT, Inc

text:
Cornerstone
Core Properties REIT, Inc

text:
Cornerstone Core
Properties REIT, Inc


dataset: buster

text:
EX-99.1
2
exhibit99_1.htm
EXHIBIT 99.1
Exhibit
99.1
For
Immediate Release
For
more information:
Contact:
Michael
Doherty
Phone: 949-673-1907
Email: mdoherty@trestlecorp.com
TRESTLE
ANNOUNCES STOCKHOLDER APPROVAL OF SALE OF ASSETS
Stockholders
Also Approved Amendment to Certificate of
Incorporation
Irvine,
CA - September 22, 2006
-
Trestle Holdings Inc. (TLHO.OB) announced today that at a special meeting of
the
stockholders held on September 20th,
two
proposals were approved. The first proposal approves the sale of substantially
all of the company's assets to Clarient, Inc. The second proposal approved an
amendment to the company's Certificate of Incorporation to effect an increase in
the authorized number of shares of common stock to 150,000,000.
--
more
--
This
press release contains statements about expected future events that are
forward-looking and subject to risks and uncertainties. For these statements,
we
claim the safe harbor for "forward-looking statements" within the meaning of
the
Private Securities Litigation Reform Act of 1995. Factors that could cause
actual results to differ and vary materially from expectations include, but
are
not limited to, our ability to consummate the asset sale, any change in business
conditions, changes in strategy, one-time events and other important factors
disclosed previously and from time to time in our filings with the Securities
and Exchange Commission. These cautionary statements by us should not be
construed as exhaustive or as any admission regarding the adequacy of
disclosures made by us. We cannot always predict or determine after the fact
what factors would cause actual results to differ materially from those
indicated by the forward-looking statements or other statements. In addition,
readers are urged to consider statements that include the terms "believes,"
"belief", "expects", "plans", "objectives", "anticipates", "intends", "targets,"
"projections", or the like to be uncertain and forward-looking. All cautionary
statements should be read as being applicable to all forward-looking statements
wherever they appear. We do not undertake any obligation to publicly update
or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.
###

label: organization

text: TRESTLE

text: Trestle Holdings Inc.

text: Clarient, Inc.

source_dataset: expertai/BUSTER

annotation_scope: BUSTER company-role spans plus reviewed organization, fund, person, and event additions with document-local surface projection; annotations remain non-exhaustive


text:
EX-99.1
2
cloveracquisitioncompletio.htm
EXHIBIT
Clover acquisition completion press release
Biogen Idec Media Contact: Biogen Idec Investor Contacts:
Lindsey Smith Ben Strain
Senior Manager, Public Affairs Senior Manager, Investor Relations
Biogen Idec Biogen Idec
Tel: (781) 464-3260 Tel: (781) 464-2442
Daniel McIntyre Claudine Prowse, Ph.D.
Senior Vice President, Public Affairs Vice President, Investor Relations
Biogen Idec Biogen Idec
Tel: (781) 464-3260 Tel: (781) 464-2442
BIOGEN IDEC COMPLETES PURCHASE OF FULL RIGHTS AND CONTROL OF TYSABRI®
Weston, Mass., April 2, 2013 -- Biogen Idec Inc. (NASDAQ: BIIB) today announced it has completed its purchase of Elan Corporation's interest in TYSABRI® (natalizumab) and has gained full strategic, commercial and decision-making rights to TYSABRI. The transaction was originally announced on February 6, 2013.
"Full ownership of TYSABRI is an important step for Biogen Idec that further solidifies our leadership in MS", said George A. Scangos, Ph.D., chief executive officer of Biogen Idec. "The powerful efficacy of TYSABRI makes it an important treatment for many people living with MS and we believe it has a solid growth trajectory for years to come. We are grateful to Elan for more than a decade of collaboration on TYSABRI, and for their work to provide a seamless transition as we finalized the transaction".
Further details and updated financial guidance will be provided during Biogen Idec's upcoming first quarter 2013 earnings announcement.
For more than two decades Biogen Idec has been a leader in multiple sclerosis (MS), offering a wide range of therapies, unsurpassed patient support, and a robust R&D program to improve the lives of people with MS. Biogen Idec also has the deepest MS pipeline in the industry with compounds that include PLEGRIDY™ (peginterferon beta-1a); daclizumab high-yield process (DAC HYP) for monthly subcutaneous administration; and an ongoing study with TYSABRI as a treatment for secondary progressive multiple sclerosis (SPMS).
About TYSABRI
TYSABRI is approved in more than 65 countries. TYSABRI is approved in the United States as a monotherapy for relapsing forms of MS, generally for patients who have had an inadequate response to, or are unable to tolerate, an alternative MS therapy due to the risk of progressive multifocal leukoencephalopathy (PML). In the European Union, it is approved for highly active relapsing-remitting MS (RRMS) in adult patients who have failed to respond to beta interferon or have rapidly evolving, severe RRMS.
TYSABRI has advanced the treatment of MS patients with its established efficacy. Data from the Phase 3 AFFIRM trial, which was published in the New England Journal of Medicine, showed that after two years, TYSABRI treatment led to a 68 percent relative reduction (p<0.001) in the annualized relapse rate when compared with placebo and reduced the relative risk of disability progression by 42-54 percent (p<0.001).
TYSABRI increases the risk of PML, an opportunistic viral infection of the brain which usually leads to death or severe disability. Infection by the JC virus (JCV) is required for the development of PML and patients who are anti-JCV antibody positive have a higher risk of developing PML. Factors that increase the risk of PML are presence of anti-JCV antibodies, prior immunosuppressant use, and longer TYSABRI treatment duration. Patients who have all three risk factors have the highest risk of developing PML. Other serious adverse events that have occurred in TYSABRI-treated patients include hypersensitivity reactions (e.g., anaphylaxis) and infections, including opportunistic and other atypical infections. Clinically significant liver injury has also been reported in the post-marketing setting. A list of adverse events can be found in the full TYSABRI product labeling for each country where it is approved.
As a result of the acquisition from Elan, TYSABRI will be marketed and distributed solely by Biogen Idec. For full prescribing information and more information about TYSABRI, please visit www.biogenidec.com.
About Biogen Idec
Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies and the company generates more than $5 billion in annual revenues. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.
About Elan
Elan Corporation, plc is a neuroscience-focused biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan's shares trade on the New York and Irish Stock Exchanges. For additional information about Elan, please visit www.elan.com.
Biogen Idec Safe Harbor Statement
This press release contains forward-looking statements, including statements about TYSABRI's growth prospects. These forward-looking statements may be accompanied by such words as "anticipate", "believe", "could", "estimate", "expect", "forecast", "intend", "may", "plan", "potential", "project", "target", "will" and other words and terms of similar meaning. You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including our dependence on our three principal products, AVONEX® (interferon beta-1a), TYSABRI and RITUXAN® (rituximab), the importance of TYSABRI's sales growth, uncertainty of success in commercializing and developing other products, product competition, the occurrence of adverse safety events with our products, changes in the availability of reimbursement for our products, adverse market and economic conditions, problems with our manufacturing processes and our reliance on third parties, failure to comply with government regulation, our ability to protect our intellectual property rights and have sufficient rights to market our products together with the cost of doing so, the risks of doing business internationally, failure to manage our growth and execute our growth initiatives, our ability to attract and retain qualified personnel, product liability claims, and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the SEC.
###

text: Biogen Idec

text: Biogen Idec

text: Biogen Idec

text: Biogen Idec

text: Biogen Idec

text: Biogen Idec

text: BIOGEN IDEC

text: TYSABRI

text: Biogen Idec Inc.

text: Elan Corporation

text: TYSABRI

text: TYSABRI

text: TYSABRI

text: Biogen Idec

text: Biogen Idec

text: TYSABRI

text: TYSABRI

text: Biogen Idec

text: Biogen Idec

text: Biogen Idec

text: TYSABRI

text: TYSABRI

text: TYSABRI

text: TYSABRI

text: TYSABRI

text: TYSABRI

text: TYSABRI

text: TYSABRI

text: TYSABRI

text: TYSABRI

text: Biogen Idec

text: TYSABRI

text: Biogen Idec

text: Biogen Idec

text: Biogen Idec

text: Elan Corporation

text: Biogen Idec

text: TYSABRI

text: TYSABRI

text: TYSABRI


text:
EX-99.1
2
a08-8628_1ex99d1.htm
EX-99.1
Exhibit 99.1
GENMAB AND PDL BIOPHARMA CLOSE SALE OF
ANTIBODY MANUFACTURING FACILITY
Summary:
Genmab's acquisition of PDL BioPharma's antibody manufacturing facility has closed.
Copenhagen, Denmark and Redwood City, Calif., USA; March 13,
2008
- Genmab A/S (OMX: GEN) and
PDL BioPharma, Inc. (Nasdaq: PDLI) today announced the closing of the
previously announced transaction under which Genmab has acquired PDL's antibody
manufacturing facility located in Brooklyn Park, Minnesota, USA for USD 240
million in cash. The transaction was first announced on February 21, 2008.
About
Genmab A/S
Genmab
is a leading international biotechnology company focused on developing fully
human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody
technology, Genmab's world class discovery and development teams have created
and developed an extensive pipeline of products for potential treatment of a
variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial
future, we remain committed to our primary goal of improving the lives of
patients who are in urgent need of new treatment options. For more information on Genmab's products and
technology, visit www.genmab.com.
About
PDL
PDL
Biopharma, Inc. is a biotechnology company focused on creating and
developing innovative antibodies that improve the lives of patients with cancer
and immunologic diseases. For more information, please visit www.pdl.com.
Forward
Looking Statement for Genmab:
This
press release contains forward looking statements. The words "believe", "expect",
"anticipate", "intend" and "plan" and similar expressions identify forward
looking statements. Actual results or performance may differ materially from
any future results or performance expressed or implied by such statements. The
important factors that could cause our actual results or performance to differ
materially include, among others, risks associated with product discovery and
development, uncertainties related to the outcome and conduct of clinical
trials including unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our inability to
manage growth, the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab is
not under an obligation to up-date statements regarding the future following
the publication of this release; nor to confirm such statements in relation to
actual results, unless this is required by law.
Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD4®; HuMax-CD20®; HuMax-EGFr™; HuMax-IL8™; HuMax-TAC™; HuMax-HepC™; HuMax-CD38™;
HuMax-CD32b™ and UniBody® are all trademarks of Genmab
A/S.
NOTE: PDL BioPharma and
the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
Genmab Contact:
Helle
Husted, Sr. Director, Investor Relations
T: +45 33 44 77 30; M: +45
25 27 47 13; E: hth@genmab.com
PDL Contacts:
Kathleen Rinehart
(Media)
Jean Suzuki (Investors)
(650) 454-2543
(650) 454-2648
kathleen.rinehart@pdl.com
jean.suzuki@pdl.com

text: GENMAB

text: Genmab

text: Genmab

text: Genmab

text: Genmab

text: Genmab

text: Genmab

text: Genmab

text: Genmab

text: Genmab

text: Genmab

text: Genmab

text: Genmab

text: Genmab

text: Genmab


text:
EX-99.1
3
d38613dex991.htm
EX-99.1
EX-99.1
Exhibit 99.1
FB Financial Corporation Completes Merger With Franklin Financial Network, Inc.
Combination creates Tennessee's premier community bank
August 17, 2020 08:30 AM Eastern Daylight Time
NASHVILLE,
Tenn.-(
BUSINESS WIRE
)-FB Financial Corporation (NYSE: FBK) ("FB Financial"), parent company of FirstBank, completed, effective August 15, 2020, its previously announced merger with Franklin Financial Network, Inc.,
parent company of Franklin Synergy Bank (collectively referred to as "Franklin").
FirstBank, the third-largest Tennessee-headquartered bank,
now has approximately $11.0 billion in assets, $7.6 billion in loans held for investment and $9.1 billion in deposits on a pro forma basis as of June 30, 2020, following the merger with Franklin.
The combination significantly enhances FirstBank's operations in the Nashville MSA, specifically in the attractive Williamson and Rutherford counties
where Franklin has a strong community presence. Pro forma for the transaction, FirstBank's deposit market share is #6 in the Nashville MSA, #1 in Williamson County and #2 in Rutherford County.
FB Financial's President and CEO Chris Holmes stated, "We are very excited to complete this transaction. We have joined forces with the leading
community bank in two of the most attractive counties in the Southeast. We look forward to building on the strong customer relationships that Franklin has fostered".
Franklin's CEO, J. Myers Jones, III, commented, "We believe that this transaction benefits all of our stakeholders, and we firmly believe that we
will be better together. Our focus will remain concentrated on our customers, and our ability to serve their needs will be stronger than ever".
With
the close of the transaction, James W. Cross IV, Melody J. Sullivan, and Jimmy E. Allen join the FB Financial board of directors.
Additionally,
Mr. Holmes commented, "This transaction provides meaningful financial benefits for our shareholders. We are now focused on the integration of the combined company; the combined franchise is well-positioned to build on our strong customer
relationships and grow our Nashville area presence".
J.P. Morgan Securities LLC served as financial advisor to FB Financial Corporation, and Wachtell, Lipton,
Rosen & Katz served as legal advisor. Evercore served as financial advisor to Franklin Financial Network, Inc., and Alston & Bird LLP served as legal advisor.
ABOUT FB FINANCIAL CORPORATION
FB Financial Corporation
(NYSE: FBK) is a bank holding company headquartered in Nashville, Tennessee. FB Financial operates through its wholly owned banking subsidiary, FirstBank, the third largest Tennessee-headquartered bank, with 87 full-service bank branches across
Tennessee, South Central Kentucky, North Alabama and North Georgia and a national mortgage business with offices across the Southeast. FirstBank serves five of the largest metropolitan markets in Tennessee and has approximately $11.0 billion in
assets.
FORWARD-LOOKING STATEMENTS
Certain
statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These
forward-looking statements include, without limitation, statements relating to the timing, benefits, costs, and synergies of the merger with Franklin Financial Network, Inc. ("Franklin") (the "Franklin merger"), and FB
Financial's future plans, results, strategies, and expectations. These statements can generally be identified by the use of the words and phrases "may", "will", "should", "could", "would,"
"goal", "plan", "potential", "estimate", "project", "believe", "intend", "anticipate", "expect", "target", "aim", "predict,"
"continue", "seek", "projection", and other variations of such words and phrases and similar expressions.
These
forward-looking statements are not historical facts, and are based upon current expectations, estimates, and projections, many of which, by their nature, are inherently uncertain and beyond FB Financial's control. The inclusion of these
forward-looking statements should not be regarded as a representation by FB Financial or any other person that such expectations, estimates, and projections will be achieved. Accordingly, FB Financial cautions shareholders and investors that any
such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, and uncertainties that are difficult to predict. Actual results may prove to be materially different from the results expressed or
implied by the forward-looking statements. A number of factors could cause actual results to differ materially from those contemplated by the forward-looking statements including, without limitation, (1) current and future economic conditions,
including the effects of declines in housing and commercial real estate prices, high unemployment rates, and any slowdown in economic growth in the local or regional economies in which we operate and/or the US economy generally, (2) the effects
of the
COVID-19
pandemic, including the magnitude and duration of the pandemic and its impact on general economic and financial market conditions and on our business and our customers' business, results
of operations, asset quality and financial condition, (3) changes in
government interest rate policies, (4) our ability to effectively manage problem credits, (5) the risk that the cost savings and any revenue synergies from the Franklin merger or
another acquisition may not be realized or may take longer than anticipated to be realized, (6) disruption from the Franklin merger with customer, supplier, or employee relationships, (7) the possibility that the costs, fees, expenses, and
charges related to the Franklin merger may be greater than anticipated, including as a result of unexpected or unknown factors, events, or liabilities, (8) the risks related to the integrations of the combined businesses following the merger,
including the risk that the integration will be materially delayed or will be more costly or difficult than expected, (9) the diversion of management time on issues related to the Franklin merger, (10) the ability of FB Financial to
effectively manage the larger and more complex operations of the combined company following the Franklin merger, (11) the risks associated with FB Financial's pursuit of future acquisitions, (12) reputational risk and the reaction of
the parties' respective customers to the Franklin merger, (13) FB Financial's ability to successfully execute its various business strategies, including its ability to execute on potential acquisition opportunities, (14) the risk
of potential litigation or regulatory action related to the Franklin merger, and (15) general competitive, economic, political, and market conditions. Further information regarding FB Financial and factors which could affect the forward-looking
statements contained herein can be found in FB Financial's Annual Report on Form
10-K
for the fiscal year ended December 31, 2019, FB Financial's quarterly reports on Form
10-Q,
and its other filings with the Securities and Exchange Commission. Many of these factors are beyond FB Financial's ability to control or predict. If one or more events related to these or other risks or
uncertainties materialize, or if the underlying assumptions prove to be incorrect, actual results may differ materially from the forward-looking statements. Accordingly, shareholders and investors should not place undue reliance on any such
forward-looking statements. Any forward-looking statement speaks only as of the date of this press release, and FB Financial undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information,
future developments or otherwise, except as required by law. New risks and uncertainties may emerge from time to time, and it is not possible for FB Financial to predict their occurrence or how they will affect the company. FB Financial qualifies
all forward-looking statements by these cautionary statements.
Contacts
MEDIA CONTACT:
Jeanie M. Rittenberry
615-313-8328
jrittenberry@firstbankonline.com
www.firstbankonline.com
FINANCIAL CONTACT:
Robert Hoehn
615-564-1212
rhoehn@firstbankonline.com
investorrelations@firstbankonline.com

text: FB Financial Corporation

text: Franklin Financial Network, Inc.

text: FB Financial Corporation

text: Franklin Financial Network, Inc.

text: J.P. Morgan Securities LLC

text: FB Financial Corporation

text:
Wachtell, Lipton,
Rosen & Katz

text: Evercore

text: Franklin Financial Network, Inc.

text: Alston & Bird LLP

text: FB FINANCIAL CORPORATION

text: FB Financial Corporation

text: Franklin Financial Network, Inc.


text:
EX-99.1
4
d809210dex991.htm
EX-99.1
EX-99.1
Exhibit 99.1
AUTOKINITON COMPLETES ACQUISITION OF TOWER INTERNATIONAL
NEW BOSTON, Mich., September
30, 2019
- Autokiniton US Holdings, Inc. ("AGG") today announced the completion of
its acquisition of Tower International, Inc. (NYSE: TOWR) ("Tower"), a leading manufacturer of engineered automotive structural metal components and assemblies, for $31 per share in cash. AGG is a subsidiary of Autokiniton Global
Group, LP, a portfolio company of KPS Capital Partners, LP ("KPS"), a leading global private equity firm with approximately $5.1 billion of assets under management, as of June 30, 2019.
The tender offer for the outstanding shares of Tower's common stock, which was made in connection with the Agreement and Plan of Merger, dated as of
July 12, 2019, by and among AGG, Tiger Merger Sub, Inc. ("Merger Sub") and Tower (the "Merger Agreement"), expired at 5:00 p.m., Eastern Daylight Time, on September 27, 2019. Following the successful
completion of the tender offer, on September 30, 2019, AGG completed the acquisition of Tower through the merger of Merger Sub with and into Tower without a vote of Tower's stockholders pursuant to Section 251(h) of the General
Corporation Law of the State of Delaware. As a result of the merger, Tower became a wholly owned subsidiary of AGG and its shares of common stock will no longer trade on the New York Stock Exchange.
In connection with the merger, each share of common stock of Tower not validly tendered into the Offer (other than certain shares and shares held by any
stockholder who is entitled to demand and has properly demanded appraisal for such shares in accordance with, and who complies in all respects with, Section 262 of the DGCL) has been cancelled and converted into the right to receive $31 per
share, in cash, net of applicable withholding, without interest in accordance with the Merger Agreement.
About Tower
Tower International is a leading manufacturer of engineered automotive structural metal components and assemblies primarily serving original equipment
manufacturers. Tower offers automotive customers a broad product portfolio, supplying body-structure stampings, frame and other chassis structures, and complex welded assemblies for small and large cars, crossovers, pickups, and sport utility
vehicles. Headquartered in Livonia, Michigan, Tower has approximately 5,700 employees and 2018 full-year revenue of $1.6 billion. Tower has 14 manufacturing facilities strategically located throughout the United States, Mexico, and Brazil
supported by five engineering and sales locations throughout the world.
About Autokiniton Global Group
AGG is a leading North American supplier of metal-formed components and complex assemblies to the automotive industry. AGG manufactures body structures,
interiors, closures, thermal management components, and chassis components. Headquartered in New Boston, Michigan, AGG has a product portfolio that is well-positioned for key automotive trends, including electrification, lightweighting, emission
reduction regulations and increased cross over utility vehicle/sport utility vehicle (CUV/SUV) penetration. AGG maintains long-standing relationships with its blue-chip customers including General Motors, Ford, Nissan, Fiat Chrysler Automobiles,
Honda, Tesla and BMW.
About KPS Capital Partners
KPS, through its affiliated management entities, is the manager of the KPS Special Situations Funds, a family of investment funds with approximately
$5.1 billion of assets under management (as of June 30, 2019). For over two decades, the Partners of KPS have worked exclusively to realize significant capital appreciation by making controlling equity investments in manufacturing and
industrial companies across a diverse array of industries, including basic materials, branded consumer, healthcare and luxury products, automotive parts, capital equipment and general manufacturing. KPS creates value for its investors by working
constructively with talented management teams to make businesses better, and generates investment returns by structurally improving the strategic position, competitiveness and profitability of its portfolio companies, rather than primarily relying
on financial leverage. The KPS Funds' portfolio companies currently have aggregate annual revenues of approximately $6.7 billion, operate 106 manufacturing facilities in 28 countries, and have approximately 24,000 employees, directly and
through joint ventures worldwide. The KPS investment strategy and portfolio companies are described in detail at www.kpsfund.com.
AGG Contact for
Media Relations:
Mark Semer or Daniel Yunger, Kekst CNC, +1 212 521 4800

text: AUTOKINITON

override: organization

text: TOWER INTERNATIONAL

text: Autokiniton US Holdings, Inc.

text: Tower International, Inc.

text: Autokiniton

label: fund

text: KPS Capital Partners, LP

text: Tower International

text: Autokiniton


text:
EX-99.1
2
a14-5064_1ex99d1.htm
EX-99.1
EXHIBIT 99.1
STARWOOD PROPERTY TRUST ANNOUNCES COMPLETION OF SPIN-OFF OF STARWOOD WAYPOINT RESIDENTIAL TRUST
- Leading Single-Family Rental Company With Vertically Integrated Platform -
- Focused on Investing in Single-Family Rentals and Non-Performing Loans -
- Positioned for Growth With Unlevered Balance Sheet, $100 Million of Cash and Anticipated $500 Million Undrawn Credit Facility -
- Listed on the New York Stock Exchange under Ticker "SWAY" -
Oakland, California (February 3, 2014) - Starwood Waypoint Residential Trust (NYSE: SWAY), a leading single-family rental real estate investment trust (REIT) announced that its common shares will begin regular trading today on the New York Stock Exchange under the ticker symbol "SWAY" following its spinoff from Starwood Property Trust, Inc. (NYSE: STWD). The spinoff transaction comprised a one-for-five distribution of Starwood Waypoint shares to stockholders of record of Starwood Property Trust on January 24, 2014. It is anticipated that Starwood Property Trust will continue to pay a quarterly dividend of $0.46 per share when it announces its 2013 year-end earnings.
"As a result of this spinoff, Starwood Property Trust stockholders are able to maintain their ownership in the premier commercial lending platform in the United States, and at the same time, participate in this newly combined company, Starwood Waypoint Residential Trust. SWAY is a veteran operator and manager of this emerging institutional asset class which is focused on capitalizing on the recovery of the largest real estate asset class in the United States, the single-family home market", said Barry Sternlicht, Chairman and Chief Executive Officer of Starwood Property Trust who will now also serve as chairman of Starwood Waypoint Residential Trust. "We believe Starwood Waypoint is perfectly positioned to capture the compelling investment opportunities in both single-family rental homes and non-performing residential loans. By leveraging Starwood Capital Group's sourcing and management expertise along with Waypoint's proven best in class operating abilities, we expect to balance our current yield requirements against longer term home appreciation potential to achieve very attractive returns on equity capital. Starwood Capital Group acquired more than 6,700 homes and non-performing loans on behalf of STWD stockholders with a geographic focus on Florida and Texas. We were very excited to combine with the established Waypoint team who have acquired, renovated and leased more than 8,000 homes since 2009. Starwood Capital Group's extensive real estate market knowledge and disciplined capital markets expertise combined with Waypoint's exceptional vertically integrated operating model perfectly position Starwood Waypoint to become a leading and differentiated company in the REIT landscape".
"We are excited to complete the successful launch of Starwood Waypoint Residential Trust as a publicly traded REIT", said Gary Beasley, Co-Chief Executive Officer of Starwood Waypoint Residential Trust. "As one of the nation's largest acquirers, owners and operators of well-located, single-family homes and attractive non-performing loan portfolios, we are extremely well positioned to continue to expand our business as a stand-alone entity".
Added Starwood Waypoint Residential Trust Co-Chief Executive Officer Doug Brien, "The combination of our experienced management team, disciplined acquisition strategy, technology-driven operational expertise, and strong balance sheet, creates a best in class platform. With this foundation, we expect to generate attractive risk-adjusted returns and increase shareholder value as we continue to opportunistically pursue our growth strategies and enhance our brand. Starwood Waypoint will have the exclusive use of Waypoint's proprietary technology platform, Compass which has been developed over five years and serves as the backbone of our entire workflow process".
The merger between Waypoint Homes and a subsidiary of Starwood Capital Group positions Starwood Waypoint Residential Trust to continue to establish a platform dedicated to investing in single-family rental homes and non-performing loans. Waypoint Homes was founded in 2009 and quickly matured into a sector pioneer, with a long-term focus on creating a superior brand in top markets across the United States. The combination of the two companies brings together Waypoint Homes' superior operating platform with Starwood Capital Group's expertise as a real estate financial sponsor to create a vertically-integrated leader in the single-family rental industry. Today, more than 550 employees nationwide are focused on managing Starwood Waypoint Residential Trust's growing portfolio of approximately 6,800 homes and non-performing loans.
About Starwood Waypoint Residential Trust
Starwood Waypoint Residential Trust is a REIT that acquires, renovates, leases, maintains and manages single-family homes. Starwood Waypoint Residential Trust is Reinventing Renting™ by building a leading, nationally recognized brand that is based on a foundation of respect for its residents and the communities in which it operates. Starwood Waypoint Residential Trust invests in non-performing loans to supplement its growth.
About Starwood Property Trust
Starwood Property Trust is focused on originating, investing in, financing and managing commercial mortgage loans and other commercial real estate debt investments, commercial mortgage-backed securities, and other commercial real estate-related debt investments. Starwood Property Trust, through its 2013 acquisition of LNR Property LLC, now also operates as special servicer in the United States and a primary and special servicer in Europe and has expanded its product offering to include fixed rate conduit loans. Starwood Property Trust also invests in residential mortgage-backed securities and residential real estate owned, and may invest in non-performing loans, commercial properties subject to net leases and residential mortgage loans. Starwood Property Trust is externally managed and advised by SPT Management, LLC, an affiliate of Starwood Capital Group, and has elected to be taxed as a real estate investment trust for U.S. federal income tax purposes.
About Starwood Capital Group
Starwood Capital Group is a private, U.S.-based investment firm with a core focus on global real estate. Since the group's inception in 1991, the firm has raised over $20 billion of equity capital and, through its various funds, has invested $18 billion representing over $41 billion in assets. Starwood Capital Group currently has $32 billion of assets under management. Starwood Capital Group maintains offices in Greenwich, Atlanta, San Francisco, Washington, D.C., Los Angeles, Chicago and Miami, and affiliated offices in London, Luxembourg, Paris and Sao Paulo. Starwood Capital Group has invested in nearly every class of real estate on a global basis, including office, retail, residential, senior housing, golf, hotels, resorts and industrial assets. Starwood Capital Group and its affiliates have successfully executed an investment strategy that includes building enterprises around core real estate portfolios in both the private and public markets. Additional information about Starwood Capital can be found at www.starwoodcapital.com.
Investor Relations
Phone: 510-987-8308
Email: IR@waypointhomes.com
Media Relations
Phil Denning or Jason Chudoba
ICR, Inc.
Phone: 203-682-8200
Jason.chudoba@icrinc.com, Phil.denning@icrinc.com

text: STARWOOD PROPERTY TRUST

text: STARWOOD WAYPOINT RESIDENTIAL TRUST

text: Starwood Waypoint Residential Trust

text: Starwood Property Trust, Inc.

text: Starwood Waypoint

text: Starwood Property Trust

text: Starwood Property Trust

text: Starwood Property Trust

text: Starwood Waypoint Residential Trust

label: person

text: Barry Sternlicht

text: Starwood Property Trust

text: Starwood Waypoint Residential Trust

text: Starwood Waypoint

text: Starwood Waypoint

text: Starwood Waypoint Residential Trust

text: Starwood Waypoint Residential Trust

text: Starwood Waypoint Residential Trust

text: Starwood Waypoint

text: Starwood Waypoint Residential Trust

text: Starwood Waypoint Residential Trust

text: Starwood Waypoint Residential Trust

text: Starwood Waypoint Residential Trust

text: Starwood Waypoint Residential Trust

text: Starwood Waypoint Residential Trust

text: Starwood Property Trust

text: Starwood Property Trust

text: Starwood Property Trust

text: Starwood Property Trust

text: Starwood Property Trust

text: SPT Management, LLC

override: fund


text:
EX-99.1
2
exh99-1.txt
PRESS RELEASE DATED DECEMBER 28, 2005
EXHIBIT 99.1
NEWS from Carrington
FOR IMMEDIATE RELEASE
For Information Contact:
Carlton E. Turner, Chief Executive Officer
(972) 518-1300
CARRINGTON COMPLETES SALE-LEASEBACK TRANSACTION
IRVING, TEXAS - December 28, 2005 - Carrington Laboratories, Inc. (Nasdaq:
CARN) today announced that it has successfully completed the sale-leaseback
of its Irving, Texas headquarters facility. The transaction was finalized
on December 23, 2005 for $4.8 million.
Carrington has agreed to lease the building for a period of 15 years,
subject to further renewal options and certain defined rights of first
refusal and repurchase. The lease is a triple-net lease with rent
escalations after the fifth and tenth years.
The sale agreement, originally entered into on October 20, 2005 with Ranier
Capital Management, L.P. was assigned by Ranier, in accordance with its
rights in the agreement, to two investor trusts based in California.
Carrington received net proceeds of approximately $4.1 million from the
sale, which are expected to be used for general corporate purposes.
Magellan Commercial Realty, Inc. represented Carrington in the transaction.
About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based,
biopharmaceutical and consumer products company currently utilizing
naturally-occurring complex carbohydrates to manufacture and market products
for mucositis, radiation dermatitis, wound and oral care, as well as to
manufacture and market the nutraceutical raw material Manapol[R] and
cosmetic raw material Hydrapol[TM]. Carrington also manufactures and markets
consumer products and manufactures quality products for other companies.
Manufacturing operations comply with cGMP standards. Carrington's DelSite
Biotechnologies subsidiary is developing its proprietary GelSite[R]
technology designed to provide controlled release of peptide and protein-
based drugs. Carrington's technology is protected by more than 130
patents in 26 countries. Select products carry the CE mark, recognized by
more than 20 countries around the world. For more information, visit
www.carringtonlabs.com.
Certain statements in this release concerning Carrington may be
forward-looking. Actual events will be dependent upon a number of
factors and risks including, but not limited to: subsequent
changes in plans by the Company's management; delays or problems
in formulation, manufacturing, distribution, production and/or
launch of new finished products; changes in the regulatory
process; changes in market trends; and a number of other factors
and risks described from time to time in the Company's filings
with the Securities & Exchange Commission, including the Form
10-Q, filed November 14, 2005.
- stop -

text: Carrington

text: Carlton E. Turner

text: CARRINGTON

text: Carrington Laboratories, Inc.

text: Carrington

text:
Ranier
Capital Management, L.P.

text: Carrington

text: Magellan Commercial Realty, Inc.

text: Carrington

text: Carrington

text: Carrington Laboratories, Inc.

text: Carrington

text: Carrington

text: Carrington

text: Carrington


text:
EX-99.1
3
a10-19659_1ex99d1.htm
EX-99.1
Exhibit 99.1
Royal Gold Announces Completion of the
Mt. Milligan Gold Stream Acquisition
DENVER, COLORADO
.
OCTOBER 20, 2010: ROYAL GOLD,
INC. (NASDAQ:RGLD; TSX:RGL)
today announced the closing of the Mt.
Milligan gold stream transaction with Thompson Creek Metals Company Inc. ("Thompson
Creek") (NYSE:TC;TSX:TCM), in which Royal Gold acquired the right to 25% of the
payable gold from the copper-gold project. Total consideration for the
transaction was $226.5 million, paid in conjunction with the closing of
Thompson Creek's acquisition of Terrane Metals Corp. ("Terrane"), and an
additional $85.0 million to be paid over the construction period of the Mt.
Milligan project. In addition, Royal
Gold will pay Thompson Creek a cash payment equal to the lesser of $400 or the
prevailing market price for each payable ounce of gold until 550,000 ounces
have been delivered to Royal Gold and the lesser of $450 or the prevailing
market price for each additional ounce thereafter.
Tony Jensen, President and Chief Executive Officer of Royal Gold
commented, "Mt. Milligan is expected to become another cornerstone asset for
Royal Gold due to its long mine life, significant production profile, and
substantial reserves. The project is a
great fit for our world class property portfolio and we look forward to our new
relationship with Thompson Creek".
The
Mt. Milligan project is in the early stages of construction, and Thompson Creek
estimates that production will commence in 2013. According to Terrane's Technical Report dated
October 23, 2009, proven and probable reserves total 482 million tonnes (0.20%
copper; 0.39 g/t gold), containing 2.1 billion pounds of copper and 6.0 million
ounces of gold. Terrane's feasibility
update study dated December 15, 2009, estimates that the reserves will support
a mine life of approximately 22 years and that Mt. Milligan will produce
approximately 262,000 ounces of gold annually during the first six years of
operation and 195,000 ounces of gold per year over the life of the mine. Mt. Milligan has received an Environmental
Assessment Certificate and a Mines Act Permit from the Province of British
Columbia and the Environmental Assessment approval from the Government of
Canada. Terrane has also secured long
lead-time equipment and has entered into an engineering, procurement and
construction management contract with an AMEC-Fluor joint venture.
Royal Gold is a precious
metals royalty company engaged in the acquisition and
management of precious metal
royalty interests. The Company owns
royalties on 187 properties on six continents, including royalties on 34
producing mines and 23 development stage projects. Royal Gold is publicly traded on the NASDAQ
Global Select Market under the symbol "RGLD" and on the Toronto Stock Exchange
under the symbol "RGL." The Company's
website is located at
www.royalgold.com
.
For further information,
please contact:
Karen Gross
Vice President and Corporate
Secretary
(303) 575-6504
Cautionary "Safe
Harbor" Statement Under the Private Securities Litigation Reform Act of
1995: With the exception of historical
matters, the matters discussed in this press release are forward-looking
statements that involve risks and uncertainties that could cause actual results
to differ materially from projections or estimates contained herein. Such forward-looking statements include Mt.
Milligan is expected to become another cornerstone asset, Mt. Milligan's long
mine life, significant production profile, and substantial reserves, the
operator's estimated date for initial production, the estimated gold and copper
reserves for the project, the reserve life of the project, the estimated
average annual production over the first six years and the life of the mine.
Like any royalty acquisition on a non-producing or not yet in development
project, the Mt. Milligan project is subject to certain risks, such as the
ability of the operator to bring the project into production and operate in
accordance with the feasibility study and the ability of Royal Gold to make
accurate assumptions regarding valuation, timing and amount of royalty
payments. Factors that could cause
actual results to differ materially from projections include, among others,
precious metals prices, the risks inherent in construction, development and
ramp up of operations of a new mine at Mt. Milligan by an operator who has not
previously operated gold mines, decisions and activities of the operator,
unanticipated grade, geological, metallurgical, processing or other problems
the operator may encounter, changes in project parameters as plans continue to
be refined, economic and market conditions, operations in land subject to First
Nations jurisdiction in Canada, as well as other factors described elsewhere in
this press release and in our Annual Report on Form 10-K, Quarterly Report on
Form 10-Q, and other filings with the Securities and Exchange Commission. In addition, acquired royalty interests on
certain projects are subject to risks associated with conducting business in a
foreign country, including application of foreign laws to contract and other
disputes, foreign environmental laws and enforcement and uncertain political
and economic environments. Most of these
factors are beyond the Company's ability to predict or control. The Company disclaims any obligation to
update any forward-looking statement made herein. Readers are cautioned not to put undue
reliance on forward-looking statements.
2

text: Royal Gold

text: ROYAL GOLD

text: Thompson Creek

text:
Thompson
Creek

text: Royal Gold

text: Thompson Creek

text:
Royal
Gold

text: Thompson Creek

text: Royal Gold

text: Tony Jensen

text: Royal Gold

text: Royal Gold

text: Thompson Creek

text: Thompson Creek

text: Royal Gold

text: Royal Gold

text: Karen Gross

text: Royal Gold


text:
EX-99.1
4
v244629_ex99-1.htm
EXHIBIT 99.1
PRESS RELEASE
Contact:
Investors/Media:
Symmetry Medical Inc.
The Ruth Group
Fred L. Hite
Zack Kubow/Lisa Cook
Senior Vice President
(646) 536-7020/7012
Chief Financial Officer
zkubow@theruthgroup.com
(574) 371-2218
lcook@theruthgroup.com
Symmetry Medical Closes Acquisition of Surgical Instruments Business of Codman & Shurtleff
Diversifies Revenue Base and Enhances Gross Margin
Provides 2012 Revenue Guidance
Warsaw, Indiana,
December 29, 2011 - Symmetry Medical Inc. (NYSE: SMA), a leading global source of innovative medical device solutions, including surgical instruments, orthopedic implants, and sterilization cases and trays, announced today that it has closed the previously announced acquisition of the surgical instruments business of Codman & Shurtleff, Inc. ("Codman"), a Johnson & Johnson company.
Beginning in the first quarter 2012, Symmetry will integrate Codman's line of surgical instruments with the Company's current hospital direct business, Specialty Surgical Instrumentation ("SSi"). The combined hospital direct general surgical instruments business will be re-named Symmetry Surgical and is expected to have more than $100 million in annual sales.
Thomas J. Sullivan, President and Chief Executive Officer of Symmetry Medical, said, "Symmetry Surgical provides several strategic benefits for our overall business, including increased revenue diversification, enhanced gross margin, a strategic instruments procurement capability in Tuttlingen, Germany, a strengthened intellectual property portfolio, and innovation driven by access to broader hospital market intelligence in additional surgical specialties. Our resulting offering will be one of the broadest and most respected product portfolios in the $1 billion market for general surgical instruments. This positions us well to continue growing our US market share in the hospital direct business, as well as building on the strong international presence established abroad by the brands acquired from Codman".
Mr. Sullivan continued, "I would like to welcome our new teammates and business partners around the world. All of us at Symmetry look forward to working with you to drive growth in the business as a trusted source of innovative medical device solutions".
Financial Guidance
The following forward-looking estimates regarding 2012 guidance reflect current market conditions and foreign currency rates. Actual results may differ materially, and the Company refers you to forward-looking statements located at the end of the press release.
For the full year 2012, including the acquisition of the surgical instruments business of Codman, the Company expects revenue to be in the range of $410 million to $425 million. As previously stated, the acquisition is expected to be breakeven on a GAAP EPS basis in 2012 and significantly accretive on a non-GAAP EPS excluding amortization basis. The Company expects to provide full year 2012 GAAP EPS as well as non-GAAP EPS excluding amortization guidance in conjunction with the release of its financial results for the fourth quarter 2011.
About Symmetry Medical Inc.
Symmetry Medical Inc. is a leading global source of innovative medical device solutions, including surgical instruments, orthopedic implants, and sterilization cases and trays. The Company's thousands of Teammates provide design, development and worldwide production capabilities for these products to customers in the orthopedic industry, other medical device markets, and specialized non-healthcare markets. Symmetry's trusted reputation and brands, broad Intellectual Property portfolio and commitment to innovation enable it to collaborate with hundreds of global medical device manufacturers as well as thousands of hospitals to provide solutions for today's needs and tomorrow's growth.
Forward-Looking Statements
Statements in the press release regarding Symmetry Medical Inc.'s business which are not historical facts may be "forward-looking statements" that involve risks and uncertainties, within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as "may", "might", "will", "should", "expect", "believe", "anticipate", "plan", "estimate", "intend", and similar words indicating possible future expectations, events or actions. Such predictive statements are not guarantees of future performance, and actual outcomes and results could differ materially from our current expectations. We refer you to the "Risk Factors" and "Forward Looking-Statements" sections in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as the Company's other filings with the SEC, which are available on the SEC's Web site at
www.sec.gov
.

text: Symmetry Medical Inc.

text: Symmetry Medical

text: Codman & Shurtleff

text: Symmetry Medical Inc.

text: Codman & Shurtleff

text: Thomas J. Sullivan

text: Symmetry Medical

text: Symmetry Medical Inc.

text: Symmetry Medical Inc.

text: Symmetry Medical Inc.


text:
EX-99.1
3
sqbg-20210421xex99d1.htm
EX-99.1
Exhibit 99.1
Sequential Brands Group Announces Sale of Heelys Brand
NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Sequential Brands Group, Inc. (Nasdaq:SQBG) announced today that it has closed on the sale of its Heelys brand to BBC International for $11 million in cash proceeds.
"The divestiture of the Heelys brand was an outcome of the Board's exploration of strategic alternatives, a process that is still underway", said William Sweedler, Executive Chairman of Sequential. "The Heelys brand was originally acquired in 2013 for a net purchase price of approximately $5.5 million (after accounting for cash on the Heelys balance sheet that we received at the time of the 2013 purchase). BBC International has been the core licensee of Heelys since 2013. We believe the brand is in great hands under BBC's leadership going forward".
The majority of the net proceeds from the sale will be used to pay down debt.
About Heelys
Founded in 2000, Heelys are patented products that feature a removable wheel located in the heel, transforming the shoes into stealth skates and giving users the freedom to seamlessly transition from walking or running to skating by shifting their weight to their heel. When the wheels are easily removed, the shoe performs just like any other shoe. The Heelys vision is to inspire kids and adults alike to be active, explore their freedom, unleash the fun and be fearless. Heelys are an attitude, a way to express themselves, push their own boundaries and experience the world around them in a truly unique way.
About Sequential Brands Group, Inc.
Sequential Brands Group, Inc. (Nasdaq: SQBG) owns, promotes, markets, and licenses a portfolio of consumer brands in the active and lifestyle categories. Sequential seeks to ensure that its brands continue to thrive and grow by employing strong brand management, and marketing teams. Sequential has licensed and intends to license its brands in a variety of consumer categories to retailers, wholesalers and distributors in the United States and around the world. For more information, please visit Sequential's website at: www.sequentialbrandsgroup.com. To inquire about licensing opportunities, please email: newbusiness@sbg-ny.com.
For Media and Investor Relations inquiries, contact:
Sequential Brands Group, Inc.
Katherine Nash
T: +1 512-757-2566
E: knash@sbg-ny.com

text: Sequential Brands Group

text: Heelys Brand

text: Sequential Brands Group, Inc.

text: Heelys brand

text: BBC International

text: Heelys brand

text: Heelys brand

text: BBC International

text: Sequential Brands Group, Inc.

text: Sequential Brands Group, Inc.

text: Sequential Brands Group, Inc.


text:
EX-99.1
2
d379059dex991.htm
PRESS RELEASE
Press Release
Exhibit 99.1
FOR IMMEDIATE RELEASE:
American Midstream Closes $51 Million Acquisition of a Majority
Interest
in Chatom Processing and Fractionation Plant
DENVER, CO-July 9, 2012-
American Midstream Partners, LP (NYSE: AMID) today
announced the closing of the acquisition of an 87.4% interest in the Chatom processing and fractionation plant and associated gathering infrastructure from affiliates of Quantum Resources Management, LLC, effective July 1, 2012. The acquisition
consideration of approximately $51 million includes a credit to American Midstream for the cash flow Chatom generated between January 1, 2012, and the acquisition closing date.
Chatom is located in Washington County, Alabama, approximately 15 miles from American Midstream's Bazor Ridge processing plant in Wayne County, Mississippi, and consists of a 25 million cubic
feet per day refrigeration processing plant, a 1,900 barrel per day fractionation unit, a 160 long-ton per day sulfur recovery unit, and a 29-mile gas gathering system.
"We are pleased to announce the closing of the Chatom acquisition", stated Brian Bierbach, President and Chief Executive Officer. "Chatom is a strategic asset that complements our Bazor
Ridge assets and is accretive on a DCF per unit basis. Given the current volatility in commodity prices, we will be waiting to increase distributions, as we had previously announced, until the asset is fully integrated into our existing operations.
Looking forward, Chatom expands our regional service offering by providing fractionation and sulfur recovery and is ideally located for future growth. We remain excited about our backlog of expansion opportunities that we believe will drive
long-term value for our unitholders".
Various unaffiliated individuals, estates, and other entities own the remaining 12.6% interest in
Chatom that American Midstream did not acquire.
American Midstream financed the acquisition with borrowings under its $200 million senior
secured revolving credit facility.
About American Midstream Partners
Denver-based American Midstream Partners is a growth-oriented limited partnership formed to own, operate, develop and acquire a diversified portfolio of natural gas midstream energy assets. The company
provides midstream services in the Gulf Coast and Southeast regions of the United States. For more information about American Midstream Partners, visit www.AmericanMidstream.com.
Forward Looking Statements
This press includes forward-looking statements. These statements relate to, among other things, projections of operational volumetrics and improvements, growth projects, cash flows and capital
expenditures. We have used the words "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project",
"should", "will", "potential" and similar terms and phrases to identify forward-looking statements in this press release. Although we believe the assumptions upon which these forward-looking statements are based are
reasonable, any of these assumptions could prove to be inaccurate and the forward-looking statements based on these assumptions could be incorrect. Our operations involve risks and uncertainties, many of which are outside our control, and any one of
which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Actual results and trends in the future may differ materially from those suggested or
implied by the forward-looking statements depending on a variety of factors which are described in greater detail in our filings with the SEC. Please see our Risk Factor disclosures included in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2011, filed with the SEC on March 19, 2012, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2012, filed with the SEC on May 14, 2012. All future written and oral forward-looking statements
attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. We undertake no obligation to update any information contained herein or to publicly release the results of any revisions to any
forward-looking statements that may be made to reflect events or circumstances that occur, or that we become aware of, after the date of this press release.

text: American Midstream

text: American Midstream Partners, LP

text: Quantum Resources Management, LLC

text: American Midstream

text: American Midstream

text: Brian Bierbach

text: American Midstream

text: American Midstream


text:
EX-99.1
6
tm2022169d9_ex99-1.htm
EXHIBIT 99.1
Exhibit 99.1
AdaptHealth Closes Previously Announced
Acquisitions of
Solara Medical Supplies and ActivStyle
Plymouth Meeting, PA -
July 2, 2020 - AdaptHealth Corp. (NASDAQ: AHCO) ("AdaptHealth" or the "Company")
, a leading
provider of home medical equipment, supplies and related services in the United States, announced today that it has closed the
previously announced acquisitions of Solara Medical Supplies, LLC ("Solara") and ActivStyle, Inc. ("ActivStyle").
The acquisitions were consummated for combined total consideration of approximately $487 million consisting of approximately $424.5
million in cash and $62.5 million in AdaptHealth Class A common stock.
AdaptHealth believes Solara is one of the largest direct-to-patient
providers of diabetes management supplies in the United States, including continuous glucose monitors (CGM), insulin pumps and
other diabetic supplies. ActivStyle is a leading direct-to-consumer supplier that provides incontinence and urology products.
"These are highly strategic, complementary and accretive
acquisitions", said Luke McGee, CEO of AdaptHealth. "We believe Solara will immediately establish AdaptHealth as a
leader in the high-growth diabetes market and advances our goal to offer high-value services to people with chronic conditions
in their homes. ActivStyle will add critical mass to important supply product categories; each company also brings to AdaptHealth
a talented group of industry professionals. The addition of Solara and ActivStyle will enrich our direct-to-patient product offerings,
create a single supply source for an expanded set of chronic care products and services, and increase our overall exposure to recurring
supply sales".
As previously announced, Steve Foreman, CEO of Solara, Gayle
Devin, CEO of ActivStyle, and key members of their respective management teams have joined AdaptHealth. Each company will continue
to operate under its current name.
AdaptHealth funded the transactions and associated costs through
a combination of incremental term loan borrowing under its existing credit agreement and equity investments of $190 million and
$35 million, respectively, by One Equity Partners and funds managed by Deerfield Management. Brad Coppens, Managing Director of
One Equity Partners, will join the board of AdaptHealth.
About AdaptHealth Corp.
AdaptHealth Corp. is a leading
provider of home healthcare equipment, medical supplies to the home and related services in the United States
. AdaptHealth
provides a full suite of medical products and solutions designed to help patients manage chronic conditions in the home, adapt
to life and thrive. Product and services offerings include (i) sleep therapy equipment, supplies and related services (including
CPAP and biPAP services) to individuals suffering from obstructive sleep apnea, (ii) home medical equipment (HME) to patients
discharged from acute care and other facilities, (iii) oxygen and related chronic therapy services in the home, and (iv) other
HME medical devices and supplies on behalf of chronically ill patients with diabetes care, wound care, urological, ostomy and
nutritional supply needs. The Company is proud to partner with an extensive and highly diversified network of referral sources,
including acute care hospitals, sleep labs, pulmonologists, skilled nursing facilities, and clinics. AdaptHealth services beneficiaries
of Medicare, Medicaid and commercial insurance payors. AdaptHealth services over approximately 1.7 million patients annually in
all 50 states through its network of 247 locations in 40 states. Learn more at
www.adapthealth.com
.
Forward-Looking Statements
This press release includes certain statements that are not
historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private
Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe,"
"may", "will", "estimate", "continue", "anticipate", "intend,"
"expect", "should", "would", "plan", "predict", "potential,"
"seem", "seek", "future", "outlook", and similar expressions that predict or indicate
future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not
limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics, projections
of market opportunity and expectations, the Company's acquisition pipeline and the impact of the recent coronavirus (COVID-19)
pandemic and our response to it. These statements are based on various assumptions and on the current expectations of Company management
and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and
are not intended to serve as, and must not be relied on, by any investor as, a guarantee, an assurance, a prediction or a definitive
statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions.
Many actual events and circumstances are beyond the control of the Company.
These forward-looking statements are subject to a number of
risks and uncertainties, including the outcome of judicial and administrative proceedings to which the Company may become a party
or governmental investigations to which the Company may become subject that could interrupt or limit the Company's operations,
result in adverse judgments, settlements or fines and create negative publicity; changes in the Company's clients'
preferences, prospects and the competitive conditions prevailing in the healthcare sector; and the impact of the recent coronavirus
(COVID-19) pandemic and the Company's response to it. A further description of such risks and uncertainties can be found
in the Company's filings with the Securities and Exchange Commission. If the risks materialize or assumptions prove incorrect,
actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks
that the Company presently knows or that the Company currently believes are immaterial that could also cause actual results to
differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company's
expectations, plans or forecasts of future events and views as of the date of this press release. The Company anticipates that
subsequent events and developments will cause the Company's assessments to change. However, while the Company may elect to
update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.
These forward-looking statements should not be relied upon as representing the Company's assessments as of any date subsequent
to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Contacts
AdaptHealth Corp
.
Brittany Lett
Vice President, Marketing
(909) 915-4983
blett@adapthealth.com
The Equity Group Inc.
Devin Sullivan
Senior Vice President
(212) 836-9608
dsullivan@equityny.com
Kalle Ahl, CFA
Vice President
(212) 836-9614
kahl@equityny.com
-
2
-

text: AdaptHealth

text: Solara Medical Supplies

text: ActivStyle

text: AdaptHealth Corp.

text: AdaptHealth

text: Solara Medical Supplies, LLC

text: ActivStyle, Inc.

text: ActivStyle

text: AdaptHealth

text: AdaptHealth

text: ActivStyle

text: AdaptHealth

text: AdaptHealth

text: ActivStyle

text: AdaptHealth

text: ActivStyle

text: Steve Foreman

text:
Gayle
Devin

text: ActivStyle

text: AdaptHealth

text: AdaptHealth

text: One Equity Partners

text: Deerfield Management

text: Brad Coppens

text: One Equity Partners

text: AdaptHealth

text: AdaptHealth Corp.

text: AdaptHealth Corp.

text: AdaptHealth

text: AdaptHealth

text: AdaptHealth

text: Brittany Lett


text:
EX-99.1
4
v422008_ex99-1.htm
EXHIBIT 99.1
Exhibit 99.1
News
From
Buena, NJ 08310
Release Date: October 13, 2015
Contact
:
Jenniffer Collins
IGI Laboratories, Inc.
(856) 697-4379
www.igilabs.com
IGI LABORATORIES, INC. ENTERS INTO AGREEMENT
TO ACQUIRE THE ASSETS OF CANADIAN PHARMACEUTICAL COMPANY,
ALVEDA PHARMACEUTICALS, INC.
Acquisition Will Deliver Contribution
To 2015 Financial Results
BUENA, NJ -
(PRNewswire) -
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey-based specialty generic pharmaceutical company, today announced it has entered
into an agreement to acquire the assets of Alveda Pharmaceuticals, Inc. for $47 million CAD in cash. Alveda Pharmaceuticals, Inc.
is a Canadian generic pharmaceutical company focused on providing the Canadian healthcare system with essential injectable pharmaceutical
products. Products are supplied through Alveda's long-term partnerships with reputable European contract manufacturing organizations.
Alveda currently markets 17 molecules in the Canadian market through its 36 injectables and is the market leader in Canada for
most of the products in the Alveda catalogue.
Jason Grenfell-Gardner, President and CEO
of IGI, commented, "This transaction should deliver contribution to our fourth quarter of 2015 financial results via a profitable
commercial platform and growing pipeline of hospital-administered injectable products in Canada. The Alveda management team has
a strong track record with the Canadian institutional supply chain including group purchasing organizations, wholesalers, and individual
hospitals. The Alveda in-house regulatory team has been quite productive, and, as a result, Alveda currently has a pipeline of
8 products, 4 of which are pending approval by Health Canada".
"This acquisition allows us
to extend our TICO strategy into Canada", continued Mr. Grenfell-Gardner. "This sector of the Canadian
market typically offers timely generic approvals from Health Canada, which, together with the Alveda team, should accelerate the
growth of IGI in Canada".
Albert Beraldo, President and CEO of Alveda Pharmaceuticals
Inc., stated, "IGI's acquisition of the Alveda product line will further accelerate development of our proven business
model. IGI provides a fantastic opportunity for the Alveda business to further expand product and service offerings for the benefit
of patients throughout Canada." The transaction is expected to close before the end of November, 2015, subject to
customary closing conditions.
Product Information
Alveda has projected net sales of approximately
$16.0M CAD for their fiscal year ended September 30, 2015.
Alveda's marketed injectable products
include:
·
atropine sulphate
·
acetylcysteine
·
dimenhydrinate
·
ergonovine maleate
·
furosemide
·
irinotecan
·
lidocaine
·
lidocaine with epinephrine
·
piperacillin tazobactam
·
methylene blue
·
naloxone
·
succinylcholine chloride
·
sodium chloride
·
sterile water
·
epinephrine
About IGI Laboratories, Inc.
IGI Laboratories is a specialty generic
pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market.
About Alveda Pharmaceuticals, Inc.
Alveda Pharmaceuticals, Inc. is a Canadian
company specializing in the sale and distribution of quality pharmaceuticals. Alveda's dedicated employees are committed
to addressing the unmet and under-met medical needs of the Canadian healthcare system.
http://www.alvedapharma.com/
Forward-Looking Statements
This press release includes certain "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements
include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release
that are not historical facts and statements identified by words such as "plan", "believe", "continue,"
"should" or words of similar meaning. Factors that could cause actual results to differ materially from these expectations
include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or
future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute
and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect
our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors;
and our inability to complete successfully future product acquisitions. These statements are based on our current beliefs or expectations
and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors"
in IGI Laboratories, Inc.'s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other periodic reports
we file with the Securities and Exchange Commission. IGI Laboratories, Inc. does not undertake any obligation to update any forward-looking
statements contained in this document as a result of new information, future events or otherwise, except as required by law.

text: IGI Laboratories, Inc.

text: IGI LABORATORIES, INC.

text: ALVEDA PHARMACEUTICALS, INC.

text: IGI Laboratories, Inc.

text: Alveda Pharmaceuticals, Inc.

text: Alveda Pharmaceuticals, Inc.

text: Alveda

text: Alveda

text: Alveda

text: Jason Grenfell-Gardner

text: IGI

text: Alveda

text: Alveda

text: Alveda

text: Alveda

text: IGI

text: Albert Beraldo

text: IGI

text: Alveda

text: IGI

text: Alveda

text: Alveda

text: Alveda

text: IGI Laboratories, Inc.

text: Alveda Pharmaceuticals, Inc.

text: Alveda Pharmaceuticals, Inc.

text: Alveda

text: IGI Laboratories, Inc.

text: IGI Laboratories, Inc.


text:
EX-99.1
2
ex99_1.htm
PRESS RELEASE 3-16-2005
Press Release 3-16-2005
Exhibit
99.1
For
Immediate Release
MAGUIRE
PROPERTIES COMPLETES ACQUISITION OF
$1.5
BILLION OFFICE PORTFOLIO
LOS
ANGELES, March 16, 2005 - Maguire Properties, Inc. (NYSE: MPG), a southern
California focused real estate investment trust, today announced that it has
completed its acquisition of a portfolio of office properties from
CommonWealth's Fifth Street Properties Portfolio. The purchase price was $1.51
billion which was funded through the assumption of $155 million of mortgage
financing, approximately $1.0 billion in new mortgage financing and proceeds
from a $450 million term loan originated by Credit Suisse First Boston. Credit
Suisse First Boston also originated a new $100 million secured revolving credit
facility which will replace the company's current $100 million secured credit
facility.
Mr.
Robert F. Maguire III, Chairman and Co-Chief Executive of Maguire Properties,
said "We are enormously pleased with the strategic acquisition of this
portfolio. The southern California properties are located in rapidly tightening
office markets with strong demand and rapidly dwindling entitlements. This
transaction, along with our recently announced San Diego Tech Center
acquisition, continues our strategy of diversifying and building strong market
share in Orange and San Diego County. Additionally, the 1.5 million square feet
of entitled development land acquired in this transaction, together with the 1.2
million square feet of entitled development land at San Diego Tech Center, will
increase our total development pipeline to over 6 million square feet at a time
when these markets are now seeing vacancy rates declining to 10% and below. We
obtained $1.29 billion of new mortgage financing either now funded or committed
at a weighted average interest rate of 5.33%. 92% or $1.19 billion is at a
weighted average interest rate of 5.4% for 7 to 10 year terms. Finally, we are
moving forward with our plans to immediately market and sell certain assets
located in less strategic markets. The proceeds of these sales will be used to
repay the term loan in the near term".
The
Company has commenced the integration of the new portfolio through the hiring of
31 CommonWealth employees who will continue to manage and lease substantially
all of the acquired properties. Additionally, the Company has retained
CommonWealth on an interim basis to provide asset management and development
services.
In
connection with the transaction, Maguire Properties obtained the following new
mortgage loans:
·
a
$273 million forward commitment for a 7-year interest only loan secured by
777 Tower, LACDB, at a fixed rate of 5.84%. The loan will fund in October
2006 with net proceeds being used to refinance the assumed mortgage loan
and repay approximately $115 million of the term loan.
·
three
separate mortgages for approximately $388 million in ten-year fixed rate
mortgage debt secured by 801 North Brand, 700 North Central and Wells
Fargo Center, which will require annual interest only payments at an
expected weighted average interest rate of 5.38% per annum through
maturity in March 2015;
·
four
separate mortgages for approximately $529 million in seven-year fixed rate
mortgage debt secured by Mission City Corporate Center, Regents Square 1
& II, Pacific Arts Plaza, One Renaissance Square, which will require
annual interest only payments at an expected weighted average interest
rate of 5.14% per annum through maturity in March
2012;
·
a
two-year variable rate mortgage for approximately $63 million secured by
Wateridge Plaza, which will require interest only payments at an expected
interest rate of 30-day LIBOR plus 2.25% through maturity. This loan will
require the purchase of a 5% LIBOR cap and can be extended for three
one-year periods upon satisfaction of certain
conditions:
·
a
two-year variable rate mortgage for approximately $42 million secured by
Austin Research Park I and II, which will require interest only payments
at an expected interest rate of 30-day LIBOR plus 2.0% through maturity.
This loan will require the purchase of a 5% LIBOR cap and can be extended
for three one-year periods upon satisfaction of certain conditions.
The $450
million term loan and $100 million revolving credit facility have five and four
year terms, respectively. The term loan and revolving credit facility will bear
interest at LIBOR plus 1.75%.
The
Company has already funded new fixed rate mortgages in the existing portfolio
for
7 to 10
year terms at a weighted average interest rate of 5% with the exception of
Gas
Company Tower. The Company is currently obtaining proposals for a $380 million,
10 month forward commitment for a 7 year interest only loan secured by Gas
Company Tower at a projected rate of 5.80%. That loan is expected to generate
excess proceeds of $100 million and would complete the Company's fixed rate debt
program.
As
previously announced, Maguire Properties plans to dispose of certain assets
located in non-strategic markets. The Company has commenced marketing of the
Austin Research Park in Austin, Texas, One Renaissance Square in Phoenix,
Arizona and the Glendale, California properties of 700 North Central and 801
North Brand. Maguire Properties has also commenced marketing Glendale Center,
which is part of its existing portfolio of Southern California properties. The
net sales proceeds are expected to be in the range of $190 -$195 million and
will also be used to pay down the $450 million term loan.
Credit
Suisse First Boston acted as a financial advisor to Maguire Properties in
connection with the acquisition.
About
Maguire Properties, Inc
.
Maguire
Properties, Inc. is the largest owner and operator of Class A office properties
in the Los Angeles central business district and is primarily focused on owning
and operating high-quality office properties in the Southern California market.
Maguire Properties, Inc. is a full-service real estate company with substantial
in-house expertise and resources in property management, marketing, leasing,
acquisitions, development and financing. For more information on Maguire
Properties, visit the Company's website at www.maguireproperties.com.
Business
Risks
This
press release contains forward-looking statements based on current expectations,
forecasts and assumptions that involve risks and uncertainties that could cause
actual outcomes and results to differ materially. These risks and uncertainties
include: risks that the closing conditions to the above-described acquisition
and/or financing will not be satisfied and the acquisition and financing not be
completed as a result thereof; risks associated with the availability and terms
of financing and the use of debt to fund acquisitions and developments,
including that increased leverage could adversely affect the company's financial
performance; risks that the company may not be able to dispose of non-strategic
assets at attractive valuations; risks associated with the failure to manage
effectively the Company's growth and expansion into new markets or to integrate
acquisitions successfully; risks and uncertainties affecting property
development and construction; general risks affecting the real estate industry
(including, without limitation, the inability to enter or renew leases,
dependence on tenants' financial condition, and competition from other
developers, owners and operators of real estate); risks associated with
downturns in the national and local economies, increases in interest rates, and
volatility in the securities markets; potential liability for uninsured losses
and environmental contamination; risks associated with our company's potential
failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended
and possible adverse changes in tax and environmental laws; and risks associated
with the Company's dependence on key personnel whose continued service is not
guaranteed. For a further list and description of such risks and uncertainties,
see the reports filed by the Company with the Securities and Exchange
Commission, including the Company's most recent annual report on form 10-K. The
Company disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.
CONTACTS:
Maguire
Properties
Peggy
Moretti
Senior
Vice President, Investor and Public Relations
(213)
613-4558
# #
#

text:
MAGUIRE
PROPERTIES

text: Maguire Properties

text: CommonWealth's Fifth Street Properties

text: Credit Suisse First Boston

text:
Credit
Suisse First Boston

text: Robert F. Maguire III

text: Maguire Properties

text: Maguire Properties

text: Maguire Properties

text: Maguire Properties

text:
Credit
Suisse First Boston

text: Maguire Properties

text: Maguire Properties

text:
Maguire
Properties

text: Maguire Properties

text:
Maguire
Properties

text:
Maguire
Properties


text:
EX-99.1
3
a07-16163_3ex99d1.htm
EX-99.1
Exhibit
99.1
Contact:
Charlene Hamrah (Investment Community)
(212) 770-7074
Joe Norton (News Media)
(212) 770-3144
AMERICAN
INTERNATIONAL GROUP, INC.
COMPLETES ACQUISITION OF 21ST CENTURY INSURANCE GROUP
NEW YORK, September 27,
2007 - American International Group, Inc. (AIG) announced that it has completed
the previously announced merger of a wholly owned subsidiary of AIG with 21st
Century Insurance Group (21st Century).
Upon consummation of the merger, AIG acquired the 39.3% of the 21st
Century shares it did not previously own.
# # #
American International
Group, Inc. (AIG), world leaders in insurance and financial services, is the
leading international insurance organization with operations in more than 130
countries and jurisdictions. AIG companies serve commercial, institutional and
individual customers through the most extensive worldwide property-casualty and
life insurance networks of any insurer. In addition, AIG companies are leading
providers of retirement services, financial services and asset management
around the world. AIG's common stock is listed on the New York Stock Exchange,
as well as the stock exchanges in Paris, Switzerland and Tokyo.
# # #

text:
AMERICAN
INTERNATIONAL GROUP, INC.

text: 21ST CENTURY INSURANCE GROUP

text: American International Group, Inc.

text:
21st
Century Insurance Group

text:
American International
Group, Inc.


text:
EX-99.1
2
exhibit99130920228-k.htm
EX-99.1
Document
Exhibit 99.1
FOR IMMEDIATE RELEASE
Newfold Digital Agrees to Acquire Deluxe's Australia Web
Hosting Operations
JACKSONVILLE, Fla. and MINNEAPOLIS, Mn. - (BUSINESS WIRE) - March 8, 2022 - Newfold Digital, a leading web and commerce technology company backed by Clearlake Capital Group, L.P. and Siris Capital Group, LLC, today announced it has entered into a definitive agreement with Deluxe (NYSE:DLX), a Trusted Payments and Business Technology™ company, to acquire Deluxe's Australia web hosting business (Hostopia Australia). The transaction is expected to close in the second quarter of 2022 subject to the satisfaction of customary closing conditions.
The Deluxe Australia web hosting business serves as a trusted hosting provider to more than 50,000 small business customers and hosts 250,000 websites. The acquisition expands Newfold Digital's presence in the Australian market and will enable the acquired customers to benefit from Newfold Digital's industry-leading brands, products, and customer support.
"Newfold Digital's mission is centered on helping businesses of all sizes build and grow an online presence, so we are confident our Australia web hosting customers will be in good hands", said Garry Capers, President of Cloud Solutions for Deluxe. "Throughout our ongoing transformation, Deluxe has concentrated our efforts on cross selling our many platforms, solutions and services to our four million small business customers and more than 4,000 enterprise and financial customers. To better manage our portfolio of businesses, and to emphasize our cross-sell abilities, it makes sense at this time to sell our Australia hosting operations to further refine our offerings in the North American market".
"As a global company, we are always looking to grow our footprint and bring our industry-leading brands and customer support to small businesses around the world", said Ed Jay, President of Newfold Digital. "A trusted web hosting service provider is essential for today's online businesses, and Deluxe's Australia web hosting business is an established platform. We are excited to welcome their customers and employees as we build upon our previous acquisitions of CrazyDomains and FreeParking to further enhance our position in the region".
"We welcome the Deluxe Australia web hosting customers to the Newfold Digital family as we continue to build upon our commitment to providing market-leading web presence solutions across the globe", said James Pade, Partner at Clearlake, and Tyler Sipprelle, Managing Director at Siris.
###
About Newfold Digital
Newfold Digital is a leading web and commerce technology company serving nearly 7 million customers globally. Established in 2021 through the combination of leading web services providers Endurance Web Presence and Web.com Group, our portfolio of brands includes: Bluehost, CrazyDomains, HostGator, Network Solutions, Register.com, Web.com and many others. We help customers of all sizes build a digital presence that delivers results. With our extensive product offerings and personalized support, we take pride in collaborating with our customers to serve their online presence needs. Learn more about Newfold Digital at Newfold.com.
About Deluxe
Deluxe, a Trusted Payments and Business Technology™ company, champions business so communities thrive. Our solutions help businesses pay and get paid and grow. For more than 100 years, Deluxe customers have relied on our solutions and platforms at all stages of their lifecycle, from start-up to maturity. Our powerful scale supports millions of small businesses, thousands of vital financial institutions and hundreds of the world's largest consumer brands, while processing more than $2.8 trillion in annual payment volume. Our reach, scale and distribution channels position Deluxe to be our customers' most trusted business partner. To learn how we can help your business, visit us at www.deluxe.com, www.facebook.com/deluxecorp, www.linkedin.com/company/deluxe, or www.twitter.com/deluxe.
About Clearlake
Clearlake Capital Group, L.P. is an investment firm founded in 2006 operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with management teams by providing patient, long-term capital to businesses that can benefit from Clearlake's operational improvement approach, O.P.S.® The firm's core target sectors are technology, industrials, and consumer. Clearlake currently has over $60 billion of assets under management, and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap.
About Siris
Siris is a leading private equity firm that invests primarily in mature technology and telecommunications companies with mission-critical products and services, facing industry changes or other significant transitions. Siris' development of proprietary research to identify opportunities and its extensive collaboration with its Executive Partners and Advisors are integral to its approach. Siris' Executive Partners and Advisors are experienced senior operating executives that actively participate in key aspects of the transaction lifecycle to help identify opportunities and drive strategic and operational value. Siris has offices in New York, Silicon Valley and West Palm Beach, and has raised nearly $6 billion in cumulative capital commitments. Learn more about Siris at www.siris.com.
Media Contacts:
For Newfold Digital:
Emily Watkins, Newfold Digital
Corporatecommunications@newfold.com
For Deluxe:
Cameron Potts, VP of Corporate Communications
651-233-7735
cameron.potts@deluxe.com
For Clearlake:
Jennifer Hurson
Lambert & Co.
845-507-0571
jhurson@lambert.com
For Siris:
Dana Gorman / Blair Hennessy, Abernathy MacGregor
212-371-5999
dtg@abmac.com / bth@abmac.com

text: Newfold Digital

text: Deluxe

text: Newfold Digital

text: Clearlake Capital Group, L.P.

text: Siris

text: Deluxe

text: Deluxe

text: Deluxe

text: Newfold Digital

text: Newfold Digital

text: Newfold Digital

text: Garry Capers

text: Deluxe

text: Deluxe

text: Ed Jay

text: Newfold Digital

text: Deluxe

text: Deluxe

text: Newfold Digital

text: James Pade

text: Tyler Sipprelle

text: Siris

text: Newfold Digital

text: Newfold Digital

text: Newfold Digital

text: Deluxe

text: Deluxe

text: Deluxe

text: Deluxe

text: Clearlake Capital Group, L.P.

text: Siris

text: Siris

text: Siris

text: Siris

text: Siris

text: Siris

text: Newfold Digital

text: Newfold Digital

text: Deluxe

text: Cameron Potts

text: Siris


text:
EX-99
3
ex992.htm
PRESS RELEASE DATED 06-10-2010
_
Exhibit 99.2
PRESS RELEASE
Contact
For Release
Lynn Felsinger
Visualant, Inc.
206.903.1351 phone
206.903.1352 fax
lynn@visualant.net
Visualant Names Jim Gingo to Board of Directors
Seattle, WA. June 10, 2010/
Business Wire
Visualant, Inc. (OTCBB: VSUL)
(the "Company) an emerging leader in security and authentication systems technology, announced today that Jim Gingo, Founder and President of TransTech Systems, Inc. has joined the Visualant Board of Directors.
Visualant has closed the acquisition of TransTech Systems, Inc. on June 8, 2010. TransTech will operate as a wholly owned subsidiary of Visualant. In addition to serving on the Visualant Board of Directors Jim Gingo will continue to serve as President of TransTech.
Ron Erickson, Visualant CEO, said, "Jim Gingo is a highly regarded industry veteran. In addition to continuing to grow TransTech, Jim will guide us as we focus on markets for the Visualant technology and explore additional acquisition opportunities. Erickson continued, "Jim's commitment and foresight is evidenced by his participation as an early member, and current Board member of the Document Security Alliance, an organization co-founded by the United States Secret Service and concerned industry representatives after the events of 9/11.
"
Jim Gingo stated, "The security and authentication marketplace is ripe for consolidation. In addition to working on acquisitions to expand our distribution capacity I will pursue product opportunities for Visualant's Spectral Pattern Matching (SPM) technology in order to create the next generation of more powerful sensors and authentication products".
About Visualant, Inc.
Visualant, Inc. is an emerging leader in security and authentication systems technology. Through its wholly-owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Safe Harbor Statement
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements (within the meaning of Section 27a of the Securities Act of 1933 and Section 21e of the Securities Exchange Act of 1934) regarding us and our business, financial condition, results of operations and prospects. Forward-looking statements in this press release reflect the good faith judgment of our management and are based on facts and factors currently known to us. Forward-looking statements are subject to risks and uncertainties, and actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements as a result of either the matters set forth or incorporated in this press release generally or certain economic and business factors, some of which may be unknown to and/or beyond the control of Visualant, Inc.. Specifically, we are exposed to various risks related to our need for additional financing to support our technology development, acquiring or investing in new businesses and ongoing operations, the sale of a significant number of our shares of common stock could depress the price of our common stock, the market price of our common stock may be volatile, and we may incur losses in the future. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. We do not undertake, and we expressly disclaim, any obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of the press release.

text: Visualant, Inc.

text: Visualant

text: Jim Gingo

text: Visualant, Inc.

text: Jim Gingo

text: TransTech Systems, Inc.

text: Visualant

text: Visualant

text: TransTech Systems, Inc.

text: Visualant

text: Visualant

text: Jim Gingo

text: Visualant

text: Jim Gingo

text: Visualant

text: Jim Gingo

text: Visualant

text: Visualant, Inc.

text: Visualant, Inc.

text: TransTech Systems, Inc.

text: Visualant, Inc.